XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenues:        
Revenue under collaborative research and development arrangements $ 1,889,988 $ 4,335,236 $ 3,686,845 $ 8,580,807
Revenue under collaborative research and development arrangements with affiliated entity 499,720 166,667 636,720 279,167
Grants and miscellaneous revenue 3,814,083 784,775 9,990,381 1,593,341
Total revenues 6,203,791 5,286,678 14,313,946 10,453,315
Operating expenses:        
Research and development 19,630,801 16,688,511 37,819,961 26,114,831
General and administrative 5,799,530 4,718,260 11,171,143 8,826,188
Gain on sale of assets (1,000,000) (1,000,000) (1,000,000) (1,000,000)
Total operating expenses 24,430,331 20,406,771 47,991,104 33,941,019
Loss from operations (18,226,540) (15,120,093) (33,677,158) (23,487,704)
Other income (expense):        
Interest and other income, net 341,131 146,332 674,201 284,608
Change in fair value of common stock warrants, net (113,775) (49,773) (520,024) (51,000)
Gain (loss) on investment in affiliated entity (705,527) 8,861,145 6,775,450 6,508,836
Net loss (18,704,711) (6,162,389) (26,747,531) (16,745,260)
Net loss attributable to non-controlling interest 0 (85,861) 0 (84,769)
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (18,704,711) $ (6,248,250) $ (26,747,531) $ (16,830,029)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders:        
Basic (in USD per share) $ (0.26) $ (0.09) $ (0.37) $ (0.26)
Diluted (in USD per share) $ (0.26) $ (0.09) $ (0.37) $ (0.27)
Weighted average number of common shares outstanding used in per share calculations:        
Basic (in shares) 72,957,159 67,655,975 72,591,986 64,198,528
Diluted (in shares) 72,957,159 67,838,738 72,591,986 64,376,523